Department of Obstetrics, Gynecology and Reproductive Science, University of California-San Diego, La Jolla, California.
Moores Cancer Center, University of California-San Diego, La Jolla, California.
Fertil Steril. 2018 Jun;109(6):1114-1120.e1. doi: 10.1016/j.fertnstert.2018.02.136.
To test whether emergency contraception use in reproductive-aged cancer survivors is higher than in the general U.S. population and evaluate factors associated with use among survivors.
A retrospective cohort study compared emergency contraception use between cancer survivors in the Reproductive Window Study on ovarian function after cancer and in the general population in the 2006-2010 National Survey for Family Growth. In a cross-sectional analysis of survivors, multivariable models were used to test associations between participant characteristics and emergency contraception use.
Not applicable.
PATIENT(S): A total of 616 female cancer survivors aged 18-40.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): Self-reported emergency contraception use.
RESULT(S): The mean age of survivors was 33.4 ± 4.7, at a mean 7.5 years since diagnosis. Breast cancer (22%), Hodgkin lymphoma (18%), and leukemia (8%) were the most common cancers. Since diagnosis, 156 (25.3%) used emergency contraception, 60% because of not otherwise using contraception. Age-adjusted prevalence of use was higher in survivors than in the general population (28.3% [95% confidence interval (CI) 24.7-31.9] vs. 12.0% [95% CI 11.1-12.9]). In multivariable analysis among survivors, nonwhite race (prevalence ratio [PR] 1.3, 95% CI 1.0-1.8), breast cancer (PR 0.6, 95% CI 0.4-1.0), partnered relationship (PR 0.6, 95% CI 0.5-0.9), and older age (age 36-40 vs. 31-35; PR 0.7, 95% CI 0.5-1.0) were associated with emergency contraception.
CONCLUSION(S): Female young adult cancer survivors were significantly more likely to use emergency contraception compared with the general population. Populations including nonwhite survivors have a higher risk, suggesting differences in family planning care. Strategies to improve contraception and decrease the need for emergency contraception are needed.
检验生殖年龄段癌症幸存者使用紧急避孕措施的比率是否高于美国一般人群,并评估幸存者使用紧急避孕措施的相关因素。
本回顾性队列研究比较了癌症幸存者在卵巢癌治疗后生殖窗口期研究(Reproductive Window Study on ovarian function after cancer)和一般人群在 2006-2010 年全国生育调查(National Survey for Family Growth)中的紧急避孕措施使用情况。在对幸存者的横断面分析中,采用多变量模型检验参与者特征与紧急避孕措施使用之间的关联。
不适用。
共纳入 616 名年龄在 18-40 岁的女性癌症幸存者。
无。
自我报告的紧急避孕措施使用情况。
幸存者的平均年龄为 33.4±4.7 岁,诊断后平均时间为 7.5 年。最常见的癌症为乳腺癌(22%)、霍奇金淋巴瘤(18%)和白血病(8%)。自诊断以来,156 名(25.3%)幸存者使用了紧急避孕措施,60%的原因是未使用其他避孕措施。调整年龄后的使用率在幸存者中高于一般人群(28.3%[95%置信区间(CI)24.7-31.9] vs. 12.0%[95% CI 11.1-12.9])。在幸存者的多变量分析中,非白人种族(比值比[PR]1.3,95% CI 1.0-1.8)、乳腺癌(PR 0.6,95% CI 0.4-1.0)、伴侣关系(PR 0.6,95% CI 0.5-0.9)和年龄较大(36-40 岁 vs. 31-35 岁;PR 0.7,95% CI 0.5-1.0)与紧急避孕措施相关。
与一般人群相比,年轻成年癌症幸存者使用紧急避孕措施的可能性显著更高。包括非白人幸存者在内的人群具有更高的风险,这表明计划生育护理存在差异。需要采取策略来改善避孕措施并减少紧急避孕措施的需求。